Pasithea Therapeutics (KTTA) Competitors $0.84 +0.09 (+11.76%) Closing price 08/28/2025 03:59 PM EasternExtended Trading$0.80 -0.04 (-4.65%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. BCAB, RLMD, AYTU, LEXX, FNCH, ABP, ATNF, AIMD, MTEX, and MBRXShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include BioAtla (BCAB), Relmada Therapeutics (RLMD), Aytu BioPharma (AYTU), Lexaria Bioscience (LEXX), Finch Therapeutics Group (FNCH), Abpro (ABP), 180 Life Sciences (ATNF), Ainos (AIMD), Mannatech (MTEX), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors BioAtla Relmada Therapeutics Aytu BioPharma Lexaria Bioscience Finch Therapeutics Group Abpro 180 Life Sciences Ainos Mannatech Moleculin Biotech Pasithea Therapeutics (NASDAQ:KTTA) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Do institutionals & insiders believe in KTTA or BCAB? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 2.7% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 11.2% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor KTTA or BCAB? In the previous week, Pasithea Therapeutics had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.94 beat Pasithea Therapeutics' score of 0.93 indicating that BioAtla is being referred to more favorably in the news media. Company Overall Sentiment Pasithea Therapeutics Positive BioAtla Positive Do analysts rate KTTA or BCAB? BioAtla has a consensus target price of $5.00, indicating a potential upside of 1,090.48%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioAtla 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is KTTA or BCAB more profitable? Pasithea Therapeutics' return on equity of -88.60% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -88.60% -81.10% BioAtla N/A -1,177.18%-137.51% Which has better valuation and earnings, KTTA or BCAB? Pasithea Therapeutics has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/A-$13.90M-$7.55-0.11BioAtla$11M2.24-$69.78M-$1.10-0.38 Which has more risk & volatility, KTTA or BCAB? Pasithea Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. SummaryBioAtla beats Pasithea Therapeutics on 8 of the 13 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.60M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.1121.0831.2726.59Price / SalesN/A356.99435.63155.76Price / CashN/A44.6737.7359.36Price / Book0.418.0910.966.68Net Income-$13.90M-$54.08M$3.27B$265.59M7 Day Performance17.29%-0.41%1.44%0.62%1 Month Performance15.30%6.23%6.24%2.61%1 Year Performance-81.60%10.45%55.09%22.34% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics1.0844 of 5 stars$0.84+11.8%N/A-81.6%$5.60MN/A-0.113News CoverageGap UpHigh Trading VolumeBCABBioAtla2.4424 of 5 stars$0.41+14.2%$5.00+1,129.7%-76.5%$20.91M$11M-0.3760High Trading VolumeRLMDRelmada Therapeutics4.6404 of 5 stars$0.66+6.0%$5.00+656.0%-70.1%$20.71MN/A-0.3010Positive NewsAYTUAytu BioPharma3.7691 of 5 stars$2.28-0.9%$10.00+338.6%-4.1%$20.60M$81M-3.17160Positive NewsLEXXLexaria Bioscience3.7847 of 5 stars$0.93-11.5%$4.00+330.6%-69.5%$20.54M$460K-1.397FNCHFinch Therapeutics Group0.3263 of 5 stars$12.70+5.9%N/A+1.6%$20.40MN/A-1.44190Gap DownABPAbproN/A$0.24-1.1%$4.00+1,550.2%N/A$19.65M$180K0.0015Positive NewsGap DownATNF180 Life Sciences0.6686 of 5 stars$3.08-6.8%N/A+53.6%$18.57MN/A-0.207Gap DownAIMDAinos1.0595 of 5 stars$4.11+7.0%N/A+26.1%$17.89M$20K-0.8240Positive NewsMTEXMannatech0.9384 of 5 stars$8.68+4.2%N/A+18.4%$17.77M$117.87M-4.25250Gap DownMBRXMoleculin Biotech2.8423 of 5 stars$0.55-5.1%$4.00+633.3%-84.3%$17.41MN/A0.0020News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies BioAtla Alternatives Relmada Therapeutics Alternatives Aytu BioPharma Alternatives Lexaria Bioscience Alternatives Finch Therapeutics Group Alternatives Abpro Alternatives 180 Life Sciences Alternatives Ainos Alternatives Mannatech Alternatives Moleculin Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access